Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in Relapsed/Refractory ALK+ ALCL
NCT03719898Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Start
- Dec 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in anaplastic large cell lymphoma (ALCL), sponsored by Fox Chase Cancer Center. Primary endpoint: Objective Response Rate at 2 years. Planned start Dec 2018; status: withdrawn.
02
Drugs
brigatinib
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT03719898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719898.